Transforming growth factor β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin

Prostate

Volumn 33, Issue 3, 1997, Pages 157-163

  Yang, Guang ^a   Timme, Terry L ^a   Park, Sang Hee ^a   Wu, Xiuyin ^a   Wyllie, Michael G ^b   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

adrenoceptor; Benign prostatic hyperplasia; Catecholamines; Doxazosin; Mouse prostate reconstitution

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TRANSFORMING GROWTH FACTOR BETA1;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APOPTOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOXAZOSIN; MALE; MICE; PROSTATE; PROSTATIC HYPERPLASIA; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030690163     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19971101)33:3<157::AID-PROS2>3.0.CO;2-G     Document Type: Article

References (21)

1. Verhoever G, Hoeben E: Pathogenesis of benign prostatic hyperplasia: potential role of mesenchymal-epithelial interaction. In Petrovich Z, Baert L (eds): "Benign Prostatic Hyperplasia." New York: Springer-Verlag, 1994, pp 17-37.
2. Lee C, Kozlowski JM, Grayhack JT: Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22:237-246.
3. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I: Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol 1994;74:585-589.
4. Lepor H, Shapiro E: Prostatic alpha adrenoceptors. Prog Clin Biol Res 1994;386:271-277.
5. Desautels M, Dulos RA: Effects of neonatal sympathectomy on brown fat development and susceptibility to high fat diet induced obesity in mice. Can J Physiol Pharmacol 1991;69:1868-1874.
6. Duncan CP, Seidler FJ, Lappi SE, Slotkin TA: Dual control of DNA synthesis by alpha- and beta-adrenergic mechanisms in normoxic and hypoxic neonatal rat brain. Dev Brain Res 1990;55:29-33.
7. Majesky MW, Daemen MJ, Schwartz SM: Alpha 1 adrenergic stimulation of platelet-derived growth factor A-chain gene expression in rat aorta. J Biol Chem 1990;265:1082-1088.
8. Nakaki DT, Nakayama M, Yamamoto S, Kato R: Alpha1 adrenergic stimulation and beta 2 adrenergic inhibition of DNA synthesis in vascular smooth muscle cells. Mol Pharmacol 1990;37:30-36.
9. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC: Retroviral transduction of transforming growth factor-β1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitution. Lab Invest 1996;74:747-760.
10. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study. Hum Pathol 1993;24:4-9.
11. Thompson TC, Southgate J, Kitchner G, Land H: Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-930.
12. Yang G, Timme TL, Park SH, Thompson TC: Transforming growth factor-β1-transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes. Prostate 1997;33:151-156.
13. Alabaster VA, Davey MJ: The α1-adrenoreceptor antagonist profile of doxazosin: Preclinical pharmacology. Br J Clin Pharmacol 1986;21:9S-17S.
14. Kaye B, Cussans NJ, Faulkner JK, Stropher DA, Reid JL: The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 1986;21:19S-25S.
15. Gavrielli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
16. Kerr JFR, Wyllie AH, Currie AH: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
17. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon DK, Flanders KC, Park SH, Thompson TC: Mesenchymal-epithelial interactions and transforming growth factor-β expression during mouse prostate morphogenesis. Endocrinology 1994;134: 1039-1045.
18. McNeil J: Origin an evolution of benign prostatic enlargement. Invest Urol 1978;16:340-345.
19. Chalazonitis A, Kalberg G, Twardzik DR, Morrison RS, Kessler JA: Transforming growth factor beta has neurotrophic actions on sensory neurons in vitro and is synergistic with nerve growth factor. Dev Biol 1992;152:121-132.
20. Flanders KC, Ludecke G, Engels S, Cissel DS, Robert AB, Kondaiah P, Lafyatis R, Sporn MB, Unsicker K: Localization and actions of transforming growth factor-beta's in the embryonic nervous system. Development 1991;113:183-199.
21. Register B, Detrée P, Leprince P, Martin D, Sadzot C, Malgrange B, Munaut C, Rigo JM, Lefebvre PP, Octave JN, Schoenen J, Moongen G: Transforming growth factor β as a neuronoglial signal during peripheral nervous system response to injury. J Neurosci Res 1993;34:32-43.